Table 2 miR-132 expression and clinicopathological factors
From: The expression and clinical significance of miR-132 in gastric cancer patients
Variables | High expression n = 33 | Low expression n =46 | P |
|---|---|---|---|
Gender | 0.618 | ||
Male | 25 | 37 | |
Female | 8 | 9 | |
Age | 0.556 | ||
<60 | 18 | 22 | |
≥60 | 15 | 24 | |
Histological grading | 0.412 | ||
Poorly-differentiated | 28 | 36 | |
Moderately-differentiated | 5 | 7 | |
Well-differentiated | 0 | 3 | |
Tumor location | 0.467 | ||
Upper third | 10 | 15 | |
Middle third | 8 | 7 | |
Lower third | 15 | 21 | |
Two-third or more | 0 | 3 | |
Tumor size (cm) | 0.862 | ||
<5 | 18 | 26 | |
≥5 | 15 | 20 | |
Nervous invasion | 0.096 | ||
Yes | 22 | 22 | |
No | 11 | 24 | |
Lymphatic tumor emboli | 0.005 | ||
Yes | 26 | 22 | |
No | 7 | 24 | |
T stage | 0.070 | ||
T1,T2 | 6 | 17 | |
T3,T4 | 27 | 29 | |
Lymph node metastasis | 0.033 | ||
Yes | 28 | 29 | |
No | 5 | 17 | |
Pathological stage | 0.016 | ||
I | 2 | 8 | |
II | 6 | 18 | |
III | 25 | 20 |